MS
BDTX icon

Maven Securities’s Black Diamond Therapeutics BDTX Stock Holding History

Maven Securities’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-187,513
Closed -$947K – 1079
2023
Q2 		$947K Buy
+187,513
New +$383K 0.01% 454
2021
Q2 		– Sell
-50,000
Closed -$1.18M – 1059
2021
Q1 		$1.18M Buy
50,000
+29,500
+144% +$796K 0.05% 353
2020
Q4 		$664K Buy
+20,500
New +$673K 0.07% 308

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Maven Securities's BDTX Position: Q3 2023 in Review

Maven Securities sold out of Black Diamond Therapeutics (BDTX) in Q3 2023, closing a stake of 187,513 shares — an estimated $947K sold.

Maven Securities first reported a position in BDTX in Q4 2020 and held it in 3 quarters. The position peaked at $1.18M in Q1 2021. 73 funds tracked by Wall St. Rank hold BDTX as of Q3 2023.

  • Maven Securities reported no remaining Black Diamond Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Maven Securities sold 187,513 Black Diamond Therapeutics shares in Q3 2023, an estimated $947K.
  • Maven Securities first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 3 quarters.
  • Maven Securities's Black Diamond Therapeutics position peaked at $1.18M in Q1 2021.
  • 73 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2023.

Based on Maven Securities's 13F filing for Q3 2023, filed 13 Nov 2023.